Rossetti Sandro, Chauveau Dominique, Walker Denise, Saggar-Malik Anand, Winearls Christopher G, Torres Vicente E, Harris Peter C
Division of Nephrology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
Kidney Int. 2002 May;61(5):1588-99. doi: 10.1046/j.1523-1755.2002.00326.x.
Genetic analysis is a useful diagnostic tool in autosomal dominant polycystic kidney disease (ADPKD), especially when imaging results are equivocal. However, molecular diagnostics by direct mutation screening has proved difficult in this disorder due to genetic and allelic heterogeneity and complexity of the major locus, PKD1.
A protocol was developed to specifically amplify the exons of PKD1 and PKD2 from genomic DNA as 150 to 450 bp amplicons. These fragments were analyzed by the technique of denaturing high-performance liquid chromatography (DHPLC) using a Wave Fragment Analysis System (Transgenomics) to detect base-pair changes throughout both genes. DHPLC-detected changes were characterized by sequencing.
Cost effective and sensitive mutation screening of the entire coding regions of PKD1 and PKD2 by DHPLC was optimized. All base-pair mutations to these genes that we previously characterized were detected as an altered DHPLC profile. To assess this method for routine diagnostic use, samples from a cohort of 45 genetically uncharacterized ADPKD patients were analyzed. Twenty-nine definite mutations were detected, 26 PKD1, 3 PKD2 and a further five possible missense mutations were characterized leading to a maximal detection rate of 76%. A high level of polymorphism of PKD1 also was detected, with 71 different changes defined. The reproducibility of the DHPLC profile enabled the recognition of many common polymorphisms without the necessity for re-sequencing.
DHPLC has been demonstrated to be an efficient and effective means for gene-based molecular diagnosis of ADPKD. Differentiating missense mutations and polymorphisms remains a challenge, but family-based segregation analysis is helpful.
基因分析是常染色体显性多囊肾病(ADPKD)中一种有用的诊断工具,尤其是当影像学结果不明确时。然而,由于基因和等位基因的异质性以及主要基因座PKD1的复杂性,通过直接突变筛查进行分子诊断在这种疾病中已被证明具有难度。
开发了一种方案,用于从基因组DNA中特异性扩增PKD1和PKD2的外显子,使其成为150至450 bp的扩增子。使用Wave片段分析系统(Transgenomics)通过变性高效液相色谱(DHPLC)技术分析这些片段,以检测两个基因中的碱基对变化。通过测序对DHPLC检测到的变化进行特征分析。
优化了通过DHPLC对PKD1和PKD2整个编码区进行经济高效且灵敏的突变筛查。我们之前鉴定的这些基因的所有碱基对突变都被检测为DHPLC图谱改变。为评估该方法用于常规诊断的情况,对一组45例基因未明确的ADPKD患者的样本进行了分析。检测到29个明确的突变,其中26个在PKD1,3个在PKD2,另外还鉴定了5个可能的错义突变,最高检测率达76%。还检测到PKD1的高度多态性,定义了71种不同变化。DHPLC图谱的可重复性使得无需重新测序就能识别许多常见多态性。
已证明DHPLC是基于基因的ADPKD分子诊断的一种有效手段。区分错义突变和多态性仍然是一个挑战,但基于家系的连锁分析会有所帮助。